VitaminSpice products now available at Walgreens
WAYNE, Pa. VitaminSpice on Thursday announced the introduction of its line of table spices supplemented with nutritionals into Walgreens.
“In addition to Walgreens, we already have interest from several significant food and ingredient manufacturers,” stated Edward Bukstel, VitaminSpice president and CEO. “The main effort now and going forward for VitaminSpice is to properly manage the massive rollout of the product to the market here [in the United States] and then worldwide.”
So far, VitaminSpice offers supplemented crushed red pepper, ground black pepper, Italian seasoning, ground cinnamon and granulated garlic.
GSK licenses OTC Xerclear; U.S. market excluded
LONDON GlaxoSmithKline on Wednesday announced an exclusive agreement for the over-the-counter rights to Medivir’s cold sore treatment Xerclear (acyclovir and hydrocortisone) in key global markets. The trade name in the U.S. market is Lipsovir, which was approved as a prescription remedy for the prevention of cold sores in July 2009.
Under the terms of the agreement, GSK gains exclusive rights to market and distribute non-prescription Xerclear as part of the Zovirax franchise, across multiple markets, including Europe, Russia, Japan, India, Australia and New Zealand. The agreement excludes North and South America, China, South Korea and Israel.
“This alliance demonstrates GSK’s ongoing commitment to invest in and expand our OTC business. It will help strengthen our dermatology portfolio across multiple territories including several key emerging markets,” stated John Clarke, president, GSK Consumer Healthcare.
GSK will assume responsibility for funding ongoing and future development of Xerclear in all territories covered by the agreement.
Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing, GSK stated.
DRJ continues sponsorship of Arthritis Foundation
ENCINITAS, Calif. DRJ on Wednesday announced the renewal of its proceeds sponsorship of the Arthritis Foundation, where a percentage of each purchase of the company’s Stopain external analgesic is donated to the foundation.
“We see the mission of the Arthritis Foundation as a crucial health issue,” stated Bob Miller, VP sales and marketing for DRJ Group. “Our company mission is to help chronic pain sufferers manage their pain so they can lead richer, more active lives. We believe that working in cooperation with the Arthritis Foundation will help this become a reality.”
DRJ Group will make a minimum contribution of $25,000 for the coming year.
Earlier this year, DRJ Group’s support for the Arthritis Foundation began appearing on Stopain labels. The labels read, in part, “Your purchase benefits the Arthritis Foundation. For every unit of Stopain products sold, DRJ Group Inc. will donate a portion of the proceeds to the Arthritis Foundation with a minimum contribution of $25,000 to help people take control of arthritis.”